275 related articles for article (PubMed ID: 33604689)
1. Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review.
Frood R; Burton C; Tsoumpas C; Frangi AF; Gleeson F; Patel C; Scarsbrook A
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3198-3220. PubMed ID: 33604689
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with
Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
Ding CY; Guo Z; Sun J; Yang WP; Li TR
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
[No Abstract] [Full Text] [Related]
4. [Prognostic Value of
Su JM; Zheng QZ; Huang WR; Deng J; Wu J; Lu HQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1181-1186. PubMed ID: 34362500
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants.
Xie M; Wu K; Liu Y; Jiang Q; Xie Y
Med Oncol; 2015 Jan; 32(1):446. PubMed ID: 25511321
[TBL] [Abstract][Full Text] [Related]
6. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of metabolic tumour volume on baseline
Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis.
Guo B; Tan X; Ke Q; Cen H
PLoS One; 2019; 14(1):e0210224. PubMed ID: 30625203
[TBL] [Abstract][Full Text] [Related]
10. A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV
Zhang YY; Song L; Zhao MX; Hu K
Cancer Med; 2019 Sep; 8(11):5137-5147. PubMed ID: 31343111
[TBL] [Abstract][Full Text] [Related]
11. Prediction of Overall Survival and Progression-Free Survival by the
Zhou Y; Ma XL; Pu LT; Zhou RF; Ou XJ; Tian R
Contrast Media Mol Imaging; 2019; 2019():5963607. PubMed ID: 31777473
[No Abstract] [Full Text] [Related]
12. Prognostic value of the baseline 18F-FDG PET/CT metabolic tumour volume (MTV) and further stratification in low-intermediate (L-I) and high-intermediate (H-I) risk NCCNIPI subgroup by MTV in DLBCL MTV predict prognosis in DLBCL.
Zhao P; Yu T; Pan Z
Ann Nucl Med; 2021 Jan; 35(1):24-30. PubMed ID: 33001389
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the prognostic values of
Lim CH; Hyun SH; Moon SH; Cho YS; Choi JY; Lee KH
Sci Rep; 2020 Jul; 10(1):12748. PubMed ID: 32728134
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the prognostic value of the metabolic volumetric parameters calculated with
Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Rodríguez Carrillo JL; Dotor de Lama A; Navarro Matilla MB; Mitjavila Casanovas M
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(4):215-222. PubMed ID: 35469793
[TBL] [Abstract][Full Text] [Related]
15. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial.
Zucca E; Cascione L; Ruberto T; Facchinelli D; Schär S; Hayoz S; Dirnhofer S; Giovanella L; Bargetzi M; Mamot C; Ceriani L
Hematol Oncol; 2020 Dec; 38(5):715-725. PubMed ID: 32947651
[TBL] [Abstract][Full Text] [Related]
16. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL.
Mikhaeel NG; Smith D; Dunn JT; Phillips M; Møller H; Fields PA; Wrench D; Barrington SF
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1209-19. PubMed ID: 26902371
[TBL] [Abstract][Full Text] [Related]
17. Are dynamic or fixed FDG-PET measures of disease of greater prognostic value in patients with relapsed/refractory diffuse large B-cell lymphoma undergoing autologous haematopoietic stem cell transplantation?
Campbell BA; Brown R; Lambertini A; Hofman MS; Bressel M; Seymour JF; Wirth A; MacManus M; Dickinson M
Br J Haematol; 2023 May; 201(3):502-509. PubMed ID: 37015002
[TBL] [Abstract][Full Text] [Related]
18. Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis.
Ceriani L; Milan L; Cascione L; Gritti G; Dalmasso F; Esposito F; Pirosa MC; Schär S; Bruno A; Dirnhofer S; Giovanella L; Hayoz S; Mamot C; Rambaldi A; Chauvie S; Zucca E
Hematol Oncol; 2022 Feb; 40(1):11-21. PubMed ID: 34714558
[TBL] [Abstract][Full Text] [Related]
19. Role of body composition and metabolic parameters extracted from baseline
Chen Y; Chen Z; Tan X; Zhang Q; Zhou Y; Yuan H; Jiang L
Ann Hematol; 2023 Oct; 102(10):2779-2789. PubMed ID: 37530853
[TBL] [Abstract][Full Text] [Related]
20. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT
Cottereau AS; Meignan M; Nioche C; Capobianco N; Clerc J; Chartier L; Vercellino L; Casasnovas O; Thieblemont C; Buvat I
Ann Oncol; 2021 Mar; 32(3):404-411. PubMed ID: 33278600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
